Melanie Abonnenc
Overview
Explore the profile of Melanie Abonnenc including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
319
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bardyn M, Martin A, Dognitz N, Abonnenc M, Dunham A, Yoshida T, et al.
Front Physiol
. 2021 Jan;
11:616457.
PMID: 33424640
Unexpectedly wide distribution (<10 to >90%) of hemoglobin oxygen saturation (sO) within red cell concentrates (RCCs) has recently been observed. Causes of such variability are not yet completely explained whereas...
2.
Sonego G, Le T, Crettaz D, Abonnenc M, Tissot J, Prudent M
J Thromb Haemost
. 2020 Oct;
19(1):233-247.
PMID: 33047470
Essentials Cysteine oxidation to sulfenic acid plays a key role in redox regulation and signal transduction. Platelet sulfenylome was studied by quantitative proteomics in pathogen inactivated platelets. One hundred and...
3.
Bardyn M, Crettaz D, Borlet M, Langst E, Martin A, Abonnenc M, et al.
Blood Transfus
. 2020 Sep;
19(4):300-308.
PMID: 32955427
Background: γ-irradiation is used to treat red blood cell (RBC) concentrates (RCCs) transfused to immunosuppressed patients. This treatment damages RBCs and increases storage lesions. Several studies have shown the beneficial...
4.
Lotens A, Abonnenc M, Malvaux N, Schuhmacher A, Prudent M, Rapaille A
Vox Sang
. 2020 Aug;
116(1):53-59.
PMID: 32797682
Background And Objectives: The antioxidant power measurement can be useful to validate the execution of the pathogen inactivation treatment of platelet concentrates. The aim of this study is to evaluate...
5.
Voruz S, Gowland P, Eyer C, Widmer N, Abonnenc M, Prudent M, et al.
Blood Transfus
. 2020 Mar;
18(6):446-453.
PMID: 32203012
Background: Nowadays, most blood products are leukocyte-reduced. After this procedure, the residual risk for transfusion transmitted cytomegalovirus (TT-CMV) is mostly attributed to cell-free viruses in the plasma of blood donors...
6.
Abonnenc M, Tissot J, Prudent M
Transfus Clin Biol
. 2018 Sep;
25(4):269-275.
PMID: 30241785
Blood products are issued from blood collection. Collected blood is immediately mixed with anticoagulant solutions that immediately induce chemical and/or biochemical modifications. Collected blood is then transformed into different blood...
7.
Sonego G, Abonnenc M, Tissot J, Prudent M, Lion N
Int J Mol Sci
. 2017 Feb;
18(2).
PMID: 28208668
Blood banks use pathogen inactivation (PI) technologies to increase the safety of platelet concentrates (PCs). The characteristics of PI-treated PCs slightly differ from those of untreated PCs, but the underlying...
8.
Abonnenc M, Crettaz D, Tacchini P, Di Vincenzo L, Sonego G, Prudent M, et al.
Transfusion
. 2016 May;
56(7):1819-27.
PMID: 27184608
Background: Pathogen inactivation treatments such as INTERCEPT aim to make sure blood and blood-derived products are free of pathogens before using them for transfusion purposes. At present, there is no...
9.
Ulrich V, Rotllan N, Araldi E, Luciano A, Skroblin P, Abonnenc M, et al.
EMBO Mol Med
. 2016 May;
8(6):643-53.
PMID: 27137489
Abnormal remodeling of atherosclerotic plaques can lead to rupture, acute myocardial infarction, and death. Enhancement of plaque extracellular matrix (ECM) may improve plaque morphology and stabilize lesions. Here, we demonstrate...
10.
Prudent M, Stauber F, Rapin A, Hallen S, Pham N, Abonnenc M, et al.
Front Mol Biosci
. 2016 Apr;
3:11.
PMID: 27066491
To date, the development of bioreactors for the study of red blood cells (RBCs, daily transfused in the case of disease or hemorrhage) has focused on hematopoietic stem cells. Despite...